Bionano Genomics Genomic Analysis Tools Suite

The latest release of Genomenon's Mastermind Genomic Search Engine indexes approximately 500,000 new genomic variants from supplemental data found in scientific publications. Most precision medicine tools have not been able to provide insight into supplemental data without manual curation due to the lack of a common file format, the company noted. Supplemental data is often published as an Excel, PDF, .csv (comma-separated value), Word, text, or image file. Genomenon said that it overcame this challenge by engineering its indexing pipeline to ingest these different file formats and applying its proprietary Genomic Language Processing (GLP) technology to index the content for easy retrieval by researchers.  

Roche has launched two Navify clinical decision support apps, called Navify Clinical Trial Match and Navify Publication Search, to help oncologists access clinical trial information and publications. Both are available on the Navify Tumor Board platform.

The Navify Clinical Trial Match app identifies clinical trial options from 11 international registries, based on patient-specific attributes such as age, sex, biomarkers, and various tumor attributes. The registries include ClinicalTrials.gov, the German Clinical Trials Registry (DRKS), and the European Clinical Trials Registry (EUCTR).

The Navify Publication Search app mines several publication sources, including PubMed, the American Society of Clinical Oncology, and the American Association of Central Cancer Registries, for relevant literature. The content of both apps is provided by MolecularMatch, a clinical informatics company.

Roche plans to add more apps, including from partners and third parties, in the future.

Viracor Eurofins has launched CMV Resistance:Letermovir, a cytomegalovirus gene sequencing assay for the detection of resistance to Prevymis (letermovir), an antiviral for use in adult hematopoietic stem cell transplant patients. The assay is available as a standalone test or as a complete panel with the other CMV drugs as CMV Resistance: Letermovir, Ganciclovir, Foscarnet, Cidofovir. Viracor Eurofins said that resistance to Prevymis has not been detected in treatment-naive patients, but noted that clinical trials have shown that resistance can develop in the UL56 gene after exposure for some HSCT patients. 

Fluidic Analytics has announced the launch of its Fluidity One system, which offers researchers the ability to observe protein behavior by measuring the size and concentrations in their native state without the need for surfaces or matrices. Based on the firm's fluidic separation and detection technology, the system analyses protein in solution and in their natural state using microfluidic diffusional sizing. The tool uses as little as 50 nanograms and produces results in less than 10 minutes. 

Asuragen announced the CE marking and launch of its QuantideX NGS DNA Hotspot 21 Kit, a targeted next-generation sequencing panel to detect variants across a multitude of tumor types. By screening for the most commonly observed variants in a simplified workflow, the research-use-only kit addresses current clinical and laboratory challenges regarding NGS testing such as long time-to-result, high assay complexiity, and lengthy data interpretation.

The assay includes the firm's cGMP manufactured, end-to-end NGS-in-a-box design, providing the reagents needed to prepare sequencing-ready libraries in as little as 24 hours. The firm's bioinformatics software examines whether enough amplifiable DNA exists. 

Xifin has launched the latest version of its lab information system, the Xifin LIS 5. The software-as-a-service-based platform includes multi-specialty workflows for molecular and next-generation sequencing. It also includes universal image management, a digital pathology consultation function, and a feature to facilitate multidisciplinary care team coordination.

Updates to the system's existing NGS module provide more specimen management, user-defined workflow steps, and the ability to support multiple lab processes. The platform's enhanced clinical trials support system now provides a project-oriented workflow. An enhanced anatomic pathology module improves the speed and functionality of new specialty workflows for gynecologic cytology, urology, and GI applications. The molecular diagnostic and genomics workflows now support FISH, gene microarray, and PCR, as well as NGS pharmacogenomics testing.

Swift Biosciences has announced the early-access availability of its Swift Amplicon HS Panels, a high-sensitivity targeted amplicon library preparation kit for next-generation sequencing of liquid biopsy samples, including cell-free DNA. According to the firm, the panels allow detection and validation of mutations occurring at 0.25 percent to 3 percent frequency among a background of host samples.

The first kit being made available is Swift's EGFR Pathway Panel, which covers clinically relevant oncology hotspots including EGFR T790, KRAS G12/G13, NRAS Q61, and BRAF V600. The firm is also building custom panels and aims to release a Sample_ID panel for fetal/maternal tracing with the same sensitivity and specificity capability.